SRC and neoplasm: To verify our findings from in vitro studies and test the efficacy of targeting Src-GSK-3 axis for prostate cancer therapy, we performed in vivo study using a PC3 cell tumor xenograft model in athymic nude mice followed by treatments with docetaxel and dasatinib, alone and in combination.